Chiome Bioscience Inc. (JP:4583) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Chiome Bioscience Inc. has initiated a Phase I clinical trial for their novel antibody drug conjugate, ADCT-701, targeting rare neuroendocrine tumors and carcinomas, with the first patient already dosed. The trial, sponsored by the National Cancer Institute, aims to establish the safe dosage and assess the drug’s pharmacokinetics and safety. ADCT-701, which includes Chiome’s cancer therapeutic antibody LIV-1205, is expected to selectively kill cancer cells due to its high efficacy and target selectivity.
For further insights into JP:4583 stock, check out TipRanks’ Stock Analysis page.